Company intelligence / Profile preview

Menarini Group

Ownership: Private
Employees: ~17000
Development stage: Commercial

Overview

Menarini has a robust commercial portfolio across multiple therapeutic areas including oncology—where it markets Tagraxofusp for BPDCN—and recently received FDA & EMA approval for Elacestrant in advanced/metastatic breast cancer. The pipeline includes both small molecules and biologics targeting high unmet needs such as antimicrobial resistance and rare cancers. The group also develops advanced diagnostic platforms for precision medicine applications

Therapeutic areas: GastroenterologyPulmonologyCardiovascularOncologyNeurologyInfectious Diseases
Modalities: Small moleculesbiologics (including monoclonal antibodies)targeted therapiesdiagnostics
Industry: Pharma

Drug pipeline

20 assets

nebivolol

Approved

19 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with Oxford BioTherapeutics on next-generation cancer drugslicensing agreements with Ryvu Therapeutics for SEL24 AML programpartnerships with academic institutions globally for R&D initiatives

Beyond the preview

Go deeper on Menarini Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Menarini Group.

Explore the full profile